Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ASELAGE STEVE | Director | Acer Therapeutics Inc. | OtherD · Sale or transfer back to the company | 483,741 | Not reported | No price reported | 0Direct | Form 4 filed 20 Nov 2023, on sec.gov (opens in a new tab)Filed 20 Nov 2023 | |
| Schelling Chris | Director, PRESIDENT AND CEO, 10% owner | Acer Therapeutics Inc. | OtherD · Sale or transfer back to the company | 2,712,529 | Not reported | No price reported | 0Direct | Form 4 filed 20 Nov 2023, on sec.gov (opens in a new tab)Filed 20 Nov 2023 | |
| PALMIN HARRY S | CHIEF FINANCIAL OFFICER | Acer Therapeutics Inc. | OtherD · Sale or transfer back to the company | 125,000 | Not reported | No price reported | 0Direct | Form 4 filed 20 Nov 2023, on sec.gov (opens in a new tab)Filed 20 Nov 2023 | |
| Davis Jefferson E | CHIEF BUSINESS OFFICER | Acer Therapeutics Inc. | OtherD · Sale or transfer back to the company | 71,645 | Not reported | No price reported | 0Direct | Form 4 filed 20 Nov 2023, on sec.gov (opens in a new tab)Filed 20 Nov 2023 | |
| DUNN JOHN MICHAEL | Director | Acer Therapeutics Inc. | OtherD · Sale or transfer back to the company | 27,380 | Not reported | No price reported | 0Direct | Form 4 filed 20 Nov 2023, on sec.gov (opens in a new tab)Filed 20 Nov 2023 | |
| Joseph Donald | See Remarks | Acer Therapeutics Inc. | OtherD · Sale or transfer back to the company | 14,285 | Not reported | No price reported | 0Direct | Form 4 filed 20 Nov 2023, on sec.gov (opens in a new tab)Filed 20 Nov 2023 | |
| Schelling Chris | Director, President & CEO, 10% owner | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 819,672 | $1.22 | $999,999.84 | 2,712,529Direct | Form 4 filed 1 Dec 2022, on sec.gov (opens in a new tab)Filed 1 Dec 2022 | |
| ASELAGE STEVE | Director | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 409,836 | $1.22 | $499,999.92 | 483,741Direct | Form 4 filed 1 Dec 2022, on sec.gov (opens in a new tab)Filed 1 Dec 2022 | |
| ASELAGE STEVE | Director | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 7,984 | $2.04 | $16,287.36 | 73,905Direct | Form 4 filed 13 Dec 2021, on sec.gov (opens in a new tab)Filed 13 Dec 2021 | |
| ASELAGE STEVE | Director | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 2,016 | $2.15 | $4,334.40 | 65,921Direct | Form 4 filed 13 Dec 2021, on sec.gov (opens in a new tab)Filed 13 Dec 2021 | |
| DUNN JOHN MICHAEL | Director | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 21,428 | $3.50 | $74,998 | 27,380Direct | Form 4 filed 28 Jul 2020, on sec.gov (opens in a new tab)Filed 28 Jul 2020 | |
| Joseph Donald | Chief Legal Officer and Secy | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 14,285 | $3.50 | $49,997.50 | 14,285Direct | Form 4 filed 28 Jul 2020, on sec.gov (opens in a new tab)Filed 28 Jul 2020 | |
| ASELAGE STEVE | Director | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 45,000 | $3.50 | $157,500 | 63,905Direct | Form 4 filed 28 Jul 2020, on sec.gov (opens in a new tab)Filed 28 Jul 2020 | |
| Schelling Chris | Director, President & CEO, 10% owner | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 142,857 | $3.50 | $499,999.50 | 1,892,857Direct | Form 4 filed 28 Jul 2020, on sec.gov (opens in a new tab)Filed 28 Jul 2020 | |
| Andrews William T. | Chief Medical Officer | Acer Therapeutics Inc. | OtherF · Shares withheld to pay tax or exercise price | 3,142 | $3.28 | $10,305.76 | 5,858Direct | Form 4 filed 4 Mar 2020, on sec.gov (opens in a new tab)Filed 4 Mar 2020 | |
| ASELAGE STEVE | Director | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 5,000 | $3.72 | $18,600 | 18,905Direct | Form 4 filed 5 Jul 2019, on sec.gov (opens in a new tab)Filed 5 Jul 2019 | |
| Andrews William T. | Chief Medical Officer | Acer Therapeutics Inc. | OtherA · Grant or award from the company | 9,000 | $0.00 | $0 | 9,000Direct | Form 4 filed 5 Mar 2019, on sec.gov (opens in a new tab)Filed 5 Mar 2019 | |
| Beeby Reshentha; Birner Hubert; Fischer Stefan; SCHUHSLER HELMUT; TVM Life Science Ventures VII L.P.; Leatt Gary; Marengere Luc | Director, 10% owner | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 275,000 | $18.00 | $4,950,000 | 1,697,709Indirect, See Footnote | Form 4 filed 22 Aug 2018, on sec.gov (opens in a new tab)Filed 22 Aug 2018 | |
| ASELAGE STEVE | Director | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 2,000 | $12.00 | $24,000 | 13,905Direct | Form 4 filed 18 Dec 2017, on sec.gov (opens in a new tab)Filed 18 Dec 2017 | |
| Leatt Gary; SCHUHSLER HELMUT; Birner Hubert; Wanless Mark; Marengere Luc; TVM Life Science Ventures VII L.P.; Fischer Stefan; TVM Life Science Ventures VI LP; TVM Life Science Ventures VI GmbH & Co KG | Director, 10% owner | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 250,000 | $12.00 | $3,000,000 | 1,422,709Indirect, See Footnote | Form 4 filed 12 Jan 2018, on sec.gov (opens in a new tab)Filed 12 Jan 2018 | |
| Leatt Gary; SCHUHSLER HELMUT; Birner Hubert; Wanless Mark; Marengere Luc; TVM Life Science Ventures VII L.P.; Fischer Stefan; TVM Life Science Ventures VI LP; TVM Life Science Ventures VI GmbH & Co KG | Director, 10% owner | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 21,271 | $12.00 | $255,252 | 248,756Indirect, See Footnote | Form 4 filed 12 Jan 2018, on sec.gov (opens in a new tab)Filed 12 Jan 2018 | |
| Leatt Gary; SCHUHSLER HELMUT; Birner Hubert; Wanless Mark; Marengere Luc; TVM Life Science Ventures VII L.P.; Fischer Stefan; TVM Life Science Ventures VI LP; TVM Life Science Ventures VI GmbH & Co KG | Director, 10% owner | Acer Therapeutics Inc. | BuyP · Open-market or private purchase | 62,062 | $12.00 | $744,744 | 725,844Indirect, See Footnote | Form 4 filed 12 Jan 2018, on sec.gov (opens in a new tab)Filed 12 Jan 2018 | |
| PALMIN HARRY S | Chief Financial Officer | Acer Therapeutics Inc. | OtherJ · Other acquisition or disposition | 125,000 | Not reported | No price reported | 125,000Direct | Form 4 filed 21 Sep 2017, on sec.gov (opens in a new tab)Filed 21 Sep 2017 | |
| DUNN JOHN MICHAEL | Director | Acer Therapeutics Inc. | OtherJ · Other acquisition or disposition | 5,952 | Not reported | No price reported | 5,952Direct | Form 4 filed 21 Sep 2017, on sec.gov (opens in a new tab)Filed 21 Sep 2017 | |
| Schelling Chris | Director, President and CEO | Acer Therapeutics Inc. | OtherJ · Other acquisition or disposition | 1,750,000 | Not reported | No price reported | 1,750,000Direct | Form 4 filed 21 Sep 2017, on sec.gov (opens in a new tab)Filed 21 Sep 2017 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.